Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
-
Publication number: 20140135387Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.Type: ApplicationFiled: May 28, 2013Publication date: May 15, 2014Applicants: Brigham Young University, Children's Hospital Center, Colorado State University Research FoundationInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Publication number: 20140135300Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
-
Publication number: 20140134206Abstract: Therapeutic use of extracts containing proanthocyanidin including treating disorders, e.g., inflammatory disorders, e.g., inflammatory bowel disease, Crohn's disease, ulcerative colitis, indeterminate colitis, microscopic colitis, collagenous colitis, and irritable bowel syndrome. Methods of increasing a subject's immunological resistance to an infection and/or treating the infection. The infection can be, e.g., a bacterial, viral, or fungal infection. The methods can include, e.g., selecting a subject that has, or is at risk of developing, an infection, e.g., a bacterial, viral, or fungal infection, or a combination thereof; providing a composition comprising at least about 10% proanthocyanidin by weight; and administering to the subj ect an amount of the composition to the subject, to thereby increase a subject's immunological resistance to an infection and/or to treat the infection.Type: ApplicationFiled: March 30, 2012Publication date: May 15, 2014Applicants: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., OCEAN SPRAY CRANBERRIES, INC.Inventors: Christina Khoo, Deann Liska, Susan S. Percival
-
Publication number: 20140127171Abstract: Methods of treating chronic post-traumatic encephalopathy (PTE) using regenerative approaches is described. In one embodiment, molecules with capability of stimulating endogenous neural stem cells is provided. In another embodiment, cell therapeutics are provided capable of addressing angiogenic deficits in patients suffering from PTE. In another embodiment, cells are utilized to induce activation of endogenous progenitor cells in the central nervous system of PTE patients. Furthermore, low level laser irradiation is disclosed as a means of treatment of PTE either through direct administration to CNS tissue for stimulation of endogenous progenitor cells and reparative processes, or together with administration of exogenous stem cells, whether autologous or allogeneic. In a further embodiment exogenous stem cells are pretreated with laser prior to administration.Type: ApplicationFiled: November 4, 2013Publication date: May 8, 2014Inventors: Roger Nocera, James Eaker
-
Patent number: 8716231Abstract: The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) or formula (II) as described herein.Type: GrantFiled: December 18, 2006Date of Patent: May 6, 2014Assignee: Janssen Pharmaceutica NVInventors: Virginia L. Smith-Swintosky, Allen B. Reitz
-
Patent number: 8716329Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 meType: GrantFiled: June 24, 2013Date of Patent: May 6, 2014Assignee: University of KentuckyInventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
-
Publication number: 20140121246Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.Type: ApplicationFiled: October 15, 2013Publication date: May 1, 2014Applicant: Metabolex, Inc.Inventors: Dong Fang Shi, Jiangao Song, Christopher J. Rabbat, Jingyuan Ma, Aaron Novack, Imad Nashashibi, Xin Chen
-
Patent number: 8710068Abstract: Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells, comprising G2/M stage arrest, in a patient by administering a compound of formula (I), (II), (III), or (IV) are also disclosed. Further disclosed herein are methods of inducing apoptosis in cancer cells in a patient by administering a compound of formula (I), (II), (III), or (IV).Type: GrantFiled: January 19, 2010Date of Patent: April 29, 2014Assignee: The Trustees Of The University Of PennsylvaniaInventors: Alan Berezov, Qiang Wang, Ramachandran Murali, Mark I. Greene
-
Patent number: 8710248Abstract: A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:Type: GrantFiled: March 9, 2012Date of Patent: April 29, 2014Assignees: The Hong Kong Polytechnic University, Wayne State University, University of South Florida, McGill UniversityInventors: Tak-Hang Chan, Wai-Har Lam, Larry Ming-Cheung Chow, Qing Ping Dou, Deborah Joyce Kuhn, Aslamuzzaman Kazi, Sheng Biao Wan, Kristin R. Landis-Piwowar
-
Patent number: 8710097Abstract: Multidrug resistance (MDR) is a major problem in cancer chemotherapy. The best characterized resistance mechanism is the one mediated by the over-expression of drug efflux transporters, permeability-glycoprotein (P-gp), which pump a variety of anticancer drugs out of the cells, resulting in lowered intracellular drug accumulation. A series of flavonoid dimers are developed in this invention, which are linked together by linker groups of various lengths. These flavonoid dimers are found to be efficient P-gp modulators that increase cytotoxicity of anticancer drugs in vitro and dramatically enhance their intracellular drug accumulation. It is found that the flavonoid dimers of this invention is also useful in reducing drug resistance in treating parasitic diseases.Type: GrantFiled: May 9, 2007Date of Patent: April 29, 2014Assignees: The Hong Kong Polytechnic University, McGill UniversityInventors: Tak-Hang Chan, Larry Ming-Cheung Chow
-
Publication number: 20140107053Abstract: The invention relates to apples comprising high concentrations of polyphenols, to processes for obtaining said apples and to uses of apples as a method of treatment of prophylaxis of cardiovascular disease, colon cancer and digestive health.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: CORESSENCE LIMITEDInventors: Richard Wood, William Barnett
-
Publication number: 20140107193Abstract: The present disclosure generally relates to nutritional compositions that are suitable for administration to adult and pediatric subjects that include a neurologic component. The neurologic component may include a flavonoid compound, such as kaempferol, fisetin, or both, and provides beneficial health benefits such as enhanced brain development and improved memory, cognition, hand-eye coordination, and enhanced focusing. Furthermore, the neurologic component may act synergistically with other brain nutrients that may be present in the compositions.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Inventors: Chenzhong Kuang, Yan Xiao, Dirk Hondmann
-
Publication number: 20140107050Abstract: The present invention is directed to a composition including N-Coumaroyldopamine and a catechol-o-methyltransferase (COMT) inhibitor for promoting weight loss in a user.Type: ApplicationFiled: October 14, 2013Publication date: April 17, 2014Applicant: Redefine Nutrition, LLCInventors: Kyung S. Kim, Bryan J. Krause
-
Publication number: 20140107051Abstract: A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 16, 2013Publication date: April 17, 2014Applicant: INSTYTUT FARMACEUTYCZNYInventors: Grzegorz GRYNKIEWICZ, Grzegorz WEGRZYN, Barbara SZECHNER, Wieslaw SZEJA, Anna TYLKI-SZYMANSKA, Alicja WEGRZYN, Joanna JAKOBKIEWICZ-BANECKA, Sylwia BARANSKA, Barbara CZARTORYSKA, Ewa PIOTROWSKA
-
Publication number: 20140105879Abstract: The invention relates to a functional flour-based food composition, in particular baked products, and a method for the preparation thereof. Specific substances of vegetable origin principally containing policosanols, isoflavones and vegetable statins are added to the flour, or to the dough for preparing the aforesaid baked products. Further components can be added to the preparation in order to enhance the effectiveness and sensory qualities thereof. The functional food composition of the invention favours the re-balancing of cholesterol and triglyceride values.Type: ApplicationFiled: April 5, 2012Publication date: April 17, 2014Inventor: Guglielmo Buonamici
-
Publication number: 20140107046Abstract: The invention provides synergistic aqueous compositions comprising at least one flavonoid, and ferulic acid, and optionally one or more additional antioxidants, for cosmetic use.Type: ApplicationFiled: October 12, 2012Publication date: April 17, 2014Applicant: L'Oreal S.A.Inventors: Zhi Pan, Jean-Thierry Simonnet, Ashleigh Murtaugh, Jamie Iannacone Spomer
-
Publication number: 20140107095Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicant: SERAGON PHARMACEUTICALS, INC.Inventors: Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Nicholas D. Smith
-
Publication number: 20140107192Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.Type: ApplicationFiled: May 18, 2012Publication date: April 17, 2014Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
-
Publication number: 20140099377Abstract: The invention relates to a continuous method for producing inorganic or organic nanoparticles having multiple nuclei functionalised with proteins, using a T-type reactor that operates at high pressure, the primary particles that form the nuclei of the nanoparticles being smaller than 10 nm and said primary particles being immersed in a proteinaceous matrix that forms the nanoparticle in sizes of between 30 nm and 500 nm. The invention also relates to the nanoparticles produced by means of said method.Type: ApplicationFiled: April 13, 2012Publication date: April 10, 2014Applicant: UNIVERSIDAD DE ANTIOQUIAInventors: Herley Casanova Yepes, Lina Paola Higuita Gonzalez
-
Publication number: 20140094465Abstract: The present invention is directed to compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.Type: ApplicationFiled: June 5, 2012Publication date: April 3, 2014Inventors: Xicheng Sun, Jian Qiu, Adam Stout
-
Publication number: 20140094513Abstract: The present invention discloses the combined treatment of memantine (N-methyl-D-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea polyphenols in preventing or treating clinical excitotoxic injury such as brain trauma, brain ischemia, epilepsy, and Alzheimer's disease.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: NATIONAL TAIWAN UNVERSITYInventors: SHOEI-YN LIN-SHIAU, JEN-KUN LIN
-
Publication number: 20140094408Abstract: A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside.Type: ApplicationFiled: June 13, 2013Publication date: April 3, 2014Inventors: Kjeld Hermansen, Soren Gregersen, Per Bendix Jeppesen
-
Publication number: 20140094512Abstract: The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in cattle by administration of a retinoic receptor antagonist or inverse agonist and compounds for use in such method.Type: ApplicationFiled: September 26, 2013Publication date: April 3, 2014Inventors: Nikolas Gunkel, Thorsten Meyer, John Michael Graettinger
-
Publication number: 20140093466Abstract: Hair care compositions including from about 0.005% to about 5% apigenin; from about 0.15% to about 12% of a solubilizing agent, wherein the solubilizing agent comprises an amine functional group; and at least about 20 weight percent of an aqueous carrier, where the composition has a pH ranging from about 3 to about 10, and methods of making the same are provided. These hair care compositions can be applied to any area of the scalp or hair where healthier hair appearance is desired.Type: ApplicationFiled: October 2, 2012Publication date: April 3, 2014Applicant: THE PROCTER & GAMBLE COMPANYInventors: Mary Jane Combs, William David Laidig, Kelly Rose Kroger-Lyons
-
Patent number: 8686028Abstract: The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from the groups consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted aroyl, optionally substituted acyloxy, optionally substituted thioamido, halogens, nitriles, esters, hydroxy, mercapto, carbontrifluoride, nitro but not limited to this; wherein R1R2 or R2R3 or R6R7 may be connected and form either a five membered ring or a six membered ring such as optionally substituted furan, optionally substituted dihydrofuran, optionally substitutedType: GrantFiled: May 14, 2009Date of Patent: April 1, 2014Assignee: Council of Scientific & Industrial ResearchInventors: Atul Goel, Amit Kumar, Sumit Chaurasia, Divya Singh, Abnish Kumar Gautam, Rashmi Pandey, Ritu Trivedi, Man Mohan Singh, Naibedya Chattopadhyay, Lakshmi Manickavasagam, Girish Kumar Jain, Anil Kumar Dwivedi
-
Patent number: 8685436Abstract: The invention relates to hydroxyflavanones, their salts and stereoisomers and their mixtures for suppressing or reducing the bitter and/or metallic taste impression. In addition, the invention relates to nutritional, nutritive or consumable preparations or oral pharmaceutical compositions, characterized in that these have an active content of hydroxyflavanones, their salts and stereoisomers or their mixtures.Type: GrantFiled: May 8, 2002Date of Patent: April 1, 2014Assignee: Symrise AGInventors: Jakob Peter Ley, Gerhard Krammer, Günter Kindel, Ian-Lucas Gatfield, Manfred Müller
-
Patent number: 8686029Abstract: Antioxidant compositions for the stabilization of fat sources against oxidation, stabilized fat source compositions, and methods of stabilizing fat sources against oxidation are described. In particular, an antioxidant emulsion that includes quercetin in addition to at least one other ingredient and a lipid carrier is described.Type: GrantFiled: May 10, 2011Date of Patent: April 1, 2014Assignee: Novus International, Inc.Inventors: Gary Reznik, David Michael T. Macaraeg
-
Patent number: 8686030Abstract: The preset invention relates to a new approach for treating a cancer or fibrosis, such as Hepatocellular carcinoma, or liver fibrosis using an extract from a plant of Graptopetalum sp., Rhodiola sp. or Echeveria sp., and prepared by extracting the plant with Dimethyl sulfoxide (DMSO), its fraction or the compound isolated from the extract.Type: GrantFiled: September 30, 2011Date of Patent: April 1, 2014Assignee: National Yang-Ming UniversityInventor: Chi-Ying Huang
-
Publication number: 20140088183Abstract: The present disclosure provides compositions and methods for alleviating inflammatory-associated diseases and conditions. These methods include administering individual and/or a mixture of multiple flavans isolated from a single or multiple Acacia genus of plants. The present disclosure also includes methods for isolating and purifying from an Acacia genus of plants a composition of flavans having dual specificity for cyclooxygenase (COX-2) and 5-lipoxygenase (5-LO) enzymes.Type: ApplicationFiled: August 20, 2013Publication date: March 27, 2014Applicant: Unigen, Inc.Inventors: Qi Jia, Timothy C. Nichols, Eric E. Rhoden, Scott Waite
-
Publication number: 20140086977Abstract: The present invention relates to a new therapy targeted at the restoration or improvement of tight junction function. Aberrant TJ function, is characteristic of many chronic skin diseases. The inventors demonstrated that plant polyphenols or flavonoids and Cis-urocanic acid modulates tight junction structure and function in mammalian keratinocytes and provided tight junction modulators, pharmaceutical compositions and methods for preventing or treating impaired tight junction function in stratified mammalian epithelia.Type: ApplicationFiled: March 23, 2012Publication date: March 27, 2014Applicant: THE UNIVERSITY OF MANCHESTERInventors: Catherine Anne O'neill, Neil Kerslake Gibbs
-
Publication number: 20140086879Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.Type: ApplicationFiled: September 23, 2013Publication date: March 27, 2014Applicant: Marrone Bio Innovations, Inc.Inventors: Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing, Sarah Lewis
-
Publication number: 20140088185Abstract: A buccally administered dosage for assisting with the relief of common digestive complaints where the dosage formed into a hard candy dosage drop, where the dosage is a sugar base infused with a botanical derivative that has concentrated active compositions in sufficient concentration to provide a soothing effect of digestive upset, and where the drop has favorable organoleptic properties.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Inventors: Dustin Garth James, Helen Kim-James
-
Publication number: 20140088184Abstract: The present invention relates to a flavonoid compound having the formula I, where R3, R5 and/or R7 is a group having the formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound having the formula (I).Type: ApplicationFiled: March 28, 2012Publication date: March 27, 2014Applicants: INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Karin Seron, Jean Dubuisson, Yves Rouille, Czeslaw Wychowski
-
Patent number: 8680141Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: GrantFiled: May 17, 2013Date of Patent: March 25, 2014Assignee: EcoBiotics LtdInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Publication number: 20140079834Abstract: The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals.Type: ApplicationFiled: April 25, 2012Publication date: March 20, 2014Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Rakesh Maurya, Preety Dixit, Ritu Trivedi, Vikram Khedgikar, Jyoti Gautam, Avinash Kumar, Divya Singh, Sheelendra Pratap Singh, (none) Wahajuddin, Girish Kumar Jain, Naibedya Chattopadhyay
-
Publication number: 20140079718Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: Northwestern UniversityInventors: Praveen Thumbikat, Anthony J. Schaeffer, Joseph Done, David J. Klumpp, Charles Rudick
-
Patent number: 8673966Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I: which are ALDH-2 inhibitors, useful for treating a patient in need thereof, for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.Type: GrantFiled: August 30, 2012Date of Patent: March 18, 2014Assignee: Gilead Sciences, Inc.Inventors: Michael Graupe, Chandrasekar Venkataramani, Jeff Zablocki
-
Publication number: 20140073611Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.Type: ApplicationFiled: May 21, 2013Publication date: March 13, 2014Applicant: National Taiwan UniversityInventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
-
Patent number: 8668921Abstract: The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula: wherein G represents a galloyl group; theasinensins represented by the formula: wherein R1 represents G or H, and R2 represents G; and theaflavins represented by the formula: wherein R1 and R2 independently represent G or H; as well as foods and beverages and medicines containing said lipase inhibitors.Type: GrantFiled: July 5, 2005Date of Patent: March 11, 2014Assignee: Suntory Holdings LimitedInventors: Masaaki Nakai, Yuko Fukui, Sumio Asami, Fumio Hashimoto
-
Patent number: 8669381Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: June 7, 2013Date of Patent: March 11, 2014Assignee: N30 Pharmaceuticals, Inc.Inventors: Xicheng Sun, Jian Qiu, Jan Wasley
-
Patent number: 8669380Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).Type: GrantFiled: October 21, 2010Date of Patent: March 11, 2014Assignee: Pfizer Inc.Inventor: Vincent Mascitti
-
Patent number: 8669284Abstract: Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a composition obtained by the method. In addition a soft gelatin capsule formulation of the compound of formula (I) obtained by incorporating the compound in a soft gelatin capsule shell comprising gelatin and a polyol plasticizer.Type: GrantFiled: June 15, 2011Date of Patent: March 11, 2014Assignees: Sucampo AG, R-Tech Ueno, Ltd.Inventors: Ryu Hirata, Yasuhiro Harada, Ryuji Ueno
-
Patent number: 8668914Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.Type: GrantFiled: July 31, 2009Date of Patent: March 11, 2014Assignees: Brigham Young University, Colorado State University Research Foundation, Children's Hospital Medical CenterInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Publication number: 20140065133Abstract: The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: UNIVERSITY OF SOUTH FLORIDAInventor: SHYAM S. MOHAPATRA
-
Publication number: 20140065153Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a JAK/STAT inhibitor.Type: ApplicationFiled: May 2, 2013Publication date: March 6, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Angela M. Christiano, Raphael Clynes
-
TRITERPENOID DERIVATIVES, BENZENOID DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
Publication number: 20140066498Abstract: The present invention relates to triterpenoid derivatives, benzenoid derivatives, and pharmaceutical compositions containing the same for treating cancers or inflammatory symptoms. According to the present invention, the triterpenoid derivatives and the benzenoid derivatives are respectively represented by the following formulas (I) and (II): wherein, R1, R2, R3, R4, R5, R6, R7, R8, , , , R1?, R2?, R3?, and R4? are defined the same as the specification.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: National Cheng Kung UniversityInventor: TIAN-SHUNG WU -
Patent number: 8664271Abstract: The present invention relates to a novel pharmaceutical formulation comprising an LTB4 agent at an alkaline pH effective to stabilize the LTB4 agent and provide a formulation with an increased shelf-life. The formulation of the present invention has an increased shelf-life of at least 24 months.Type: GrantFiled: September 20, 2005Date of Patent: March 4, 2014Assignee: LTB4 Sweden ABInventor: Pierre Borgeat
-
Patent number: 8664264Abstract: The present invention provides an antiproliferative compound having a structural formula where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R2 and R3 are hydrogen or R4; R4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R6, wherein R6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.Type: GrantFiled: February 28, 2012Date of Patent: March 4, 2014Assignee: Research Development FoundationInventors: Bob G. Sanders, Kimberly Kline, Weiping Yu
-
Publication number: 20140057837Abstract: Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become brown adipose tissue in a subject include the administration of one or more agents. The agent can increase or induce hypothalamic expression of BDNF, can be a TrkB receptor agonist or a beta-3 adrenergic receptor agonist, or encode an agonist that modulates a hypothalamic-adipocyte axis.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Inventors: Matthew During, Lei Cao
-
Patent number: 8658692Abstract: Disclosed herein are a method for preparation of an inclusion-complex including a physiologically active hydrophobic substance in cyclodextrin and a derivative thereof, and use of the inclusion-complex prepared by the same. More particularly, the present invention provides a method for preparing an inclusion-complex, which includes agitating cyclodextrin and a derivative thereof in an agitator at high speed, spraying a physiologically active hydrophobic substance dissolved in alcohol onto the agitator, and drying and crushing the mixture obtained from the preceding step and, in addition, use of the prepared inclusion-complex. The present inventive method has merits of reduced inclusion time and increased inclusion rate. The prepared inclusion-complex has excellent cell and collagen proliferation effects compared to physiologically active hydrophobic substances which were not inclusion processed, thereby being used in production of a cosmetic composition with improved anti-wrinkle and anti-ageing effects.Type: GrantFiled: September 3, 2008Date of Patent: February 25, 2014Assignee: Macrocare Tech., Ltd.Inventors: Moo-Sung Kim, Sang-Rin Lee, Yong-Dae Park